Virus-like particle conjugates
This invention is directed to immunogenic composition, conjugates, virus-lie particles (VLP) compositions, vaccines and methods directed to the treatment and/or prevent of infection by Human Papillomavirus.
1. An immunogenic composition comprising multivalent virus-like particles (VLPs) comprised of L1 or L2 proteins of Human papilloma virus (HPV) coupled to a heterobifunctional, homobifunctional, or multifunctional spacer arm which is coupled to a carrier protein, wherein the carrier protein is coupled to another a heterobifunctional, homobifunctional, or multifunctional spacer arm which is coupled to another L1 or L2 protein of HPV.
2. The immunogenic composition of claim 1 , wherein the HPV comprises serotype 6, 11, 16, 18, 31, 33, 45, 52, and/or 58.
3. The immunogenic composition of claim 1 , wherein at least one spacer arm comprises NH 2 -PEG-NH 2 /NHS, NHS/NH 2 -PEG-COOH, Mal-PEG-NH 2 , Mal-PEG-NHS, CHO-PEG-CHO, SH-PEG-NH 2 , ADH, HZ-PEG-HZ, SMPH, SMCC, or 4-Arm-PEG-NH 2 .
4. The immunogenic composition of claim 1 , wherein the carrier protein comprises tetanus toxoid, diphtheria toxoid, CRM197, tetanus toxoid fragments (TTHc), N. meningitidis protein PorB, RSV virus proteins, B. Pertussis proteins, Pertussis toxoid (PT), adenylate cyclase toxin (ACT), 69 KDa protein, Human Papilloma viral protein antigens, Human Papilloma virus VLP forms, Hepatitis B virus core antigen, Hepatitis B virus VLP forms, derivatives of HBsAg, and/or combinations thereof.
5. The immunogenic composition of claim 1 , further comprising an adjuvant.
6. The immunogenic composition of claim 5 , wherein the adjuvant comprises aluminum salt, calcium phosphate, a liposome of monophosphoryl lipid A (MPLA), saponin QS-21, TLR ligands, and/or a potent TLR4/7/8/9 agonists.
7. The immunogenic composition of claim 6 , wherein the aluminum salt is selected from the group consisting of aluminum phosphate, aluminum sulfate and/or aluminum hydroxide.
8. The immunogenic composition of claim 1 , wherein the VLP is obtained or derived from HPV L1 protein and HPV L2 protein and the carrier protein is CRM197.
9. The immunogenic composition of claim 1 , wherein the VLPs are bi-valent L1 VLP conjugates, the HPV is serotype 16 and/or 18, and the carrier protein is CRM197.
10. The immunogenic composition of claim 1 , wherein the VLPs are bi-valent L1 VLP conjugates, the HPV is serotype 6 and/or 11, and the carrier protein is CRM197.
11. The immunogenic composition of claim 1 , wherein the VLPs are bi-valent L1 VLP conjugates, the HPV is serotype 31 and/or 33, and the carrier protein is CRM197.
12. The immunogenic composition of claim 1 , wherein the VLPs are bi-valent L1 VLP conjugates, the HPV is serotype 45 and/or 52, and the carrier protein is CRM197.
13. The immunogenic composition of claim 1 , wherein the VLPs are bi-valent L1 VLP conjugates, the HPV is serotype 58, and the carrier protein is CRM197.
14. The immunogenic composition of claim 1 , wherein the VLPs comprise L1 protein conjugated to L2 protein, and the carrier protein is CRM197.
15. The immunogenic composition of claim 1 , wherein administration to a patient boosts the efficacy of a conventional vaccine.
16. An immunogenic composition comprising multivalent virus-like particles (VLPs) comprised of L1 protein of Human papilloma virus (HPV), coupled to a spacer arm which is coupled to a carrier protein and the carrier protein is coupled to another spacer arm which is coupled to another L1 or L2 protein of HPV, wherein:
the HPV comprises serotype 6, 11, 16, 18, 31, 33, 45, 52, and/or 58;
at least one spacer arm comprises a hetero-bifunctional spacer arm, which contains polyethylene glycol (PEG) and a hydrazide or modified hydrazide; and
the carrier protein comprises tetanus toxoid or diphtheria toxoid.
17. The immunogenic composition of claim 16 , further comprising an adjuvant.
18. An immunogenic composition comprising multivalent virus-like particles (VLPs) comprised of L2 protein of Human papilloma virus (HPV), coupled to a spacer arm which is coupled to a carrier protein and the carrier protein is coupled to another spacer arm which is coupled to another L1 or L2 protein of HPV, wherein:
the HPV comprises serotype 6, 11, 16, 18, 31, 33, 45, 52, and/or 58;
at least one spacer arm comprises a hetero-bifunctional spacer arm, which contains polyethylene glycol (PEG) and a hydrazide or modified hydrazide; and
the carrier protein comprises tetanus toxoid or diphtheria toxoid.
19. The immunogenic composition of claim 18 , further comprising an adjuvant.
20. The immunogenic composition of claim 16 , wherein at least one spacer arm comprises NH 2 -PEG-NH 2 /NHS, NHS/NH 2 -PEG-COOH, Mal-PEG-NH 2 , Mal-PEG-NHS, CHO-PEG-CHO, SH-PEG-NH 2 , ADH, HZ-PEG-HZ, SMPH, SMCC, or 4-Arm-PEG-NH 2 .
21. The immunogenic composition of claim 18 , wherein each spacer arm comprises NH 2 -PEG-NH 2 /NHS, NHS/NH 2 -PEG-COOH, Mal-PEG-NH 2 , Mal-PEG-NHS, CHO-PEG-CHO, SH-PEG-NH 2 , ADH, HZ-PEG-HZ, SMPH, SMCC, or 4-Arm-PEG-NH 2 .
22. The immunogenic composition of claim 1 , wherein upon administration to a patient of two doses at about 20-40 μg per dose generates a protective immune response against HPV.
23. The immunogenic composition of claim 16 , wherein upon administration to a patient of two doses at about 20-40 μg per dose generates a protective immune response against HPV.
24. The immunogenic composition of claim 18 , wherein upon administration to a patient of two doses at about 20-40 μg per dose generates a protective immune response against HPV.
25. The immunogenic composition of claim 1 , wherein upon administration to a patient of two doses at about 8-10 μg per dose generates a protective immune response against HPV.
26. The immunogenic composition of claim 16 , wherein upon administration to a patient of two doses at about 8-10 μg per dose generates a protective immune response against HPV.
27. The immunogenic composition of claim 18 , wherein upon administration to a patient of two doses at about 8-10 μg per dose generates a protective immune response against HPV.
28. The immunogenic composition of claim 25 , wherein a second dose is administered about two months after a first dose.
29. The immunogenic composition of claim 26 , wherein a second dose is administered about two months after a first dose.
30. The immunogenic composition of claim 27 , wherein a second dose is administered about two months after a first dose.